Inventiva S.A. (NASDAQ:IVA) Short Interest Update

Inventiva S.A. (NASDAQ:IVA - Get Free Report) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 853,400 shares, an increase of 562.1% from the September 30th total of 128,900 shares. Based on an average daily volume of 201,000 shares, the short-interest ratio is presently 4.2 days.

Inventiva Stock Performance

Shares of NASDAQ IVA traded up $0.18 during mid-day trading on Friday, hitting $2.66. 52,505 shares of the stock were exchanged, compared to its average volume of 80,913. The stock's fifty day simple moving average is $2.21 and its two-hundred day simple moving average is $2.75. Inventiva has a twelve month low of $1.53 and a twelve month high of $4.75.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IVA. HC Wainwright cut their target price on Inventiva from $14.00 to $13.00 and set a "buy" rating for the company in a research report on Tuesday, October 15th. Stifel Nicolaus dropped their price objective on Inventiva from $25.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, September 26th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $16.25.

Hedge Funds Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC acquired a new position in shares of Inventiva S.A. (NASDAQ:IVA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,490 shares of the company's stock, valued at approximately $38,000. 19.06% of the stock is owned by institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.